Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 2/20 | 0.42 |
| ▸ | AGXT | P21549 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411538 | 0.98 | MAOA (0.45) | MAOAMAOBIDO1DHFRAGXT | |
| SCHEMBL10942039 | 0.80 | TSHR (0.44) | IDO1DHFRAGXTOPRM1OPRD1 | |
| SCHEMBL11587465 | 0.77 | TSHR (0.41) | IDO1DHFRAGXTOPRM1OPRD1 | |
| SCHEMBL11540623 | 0.77 | TSHR (0.41) | IDO1DHFRAGXTOPRM1OPRD1 | |
| SCHEMBL2237483 | 0.77 | TSHR (0.41) | IDO1DHFRAGXTOPRM1OPRD1 | |
| SCHEMBL21638945 | 0.74 | TSHR (0.43) | IDO1AGXTOPRM1OPRD1OPRK1 | |
| SCHEMBL3645094 | 0.74 | DHFR (0.38) | IDO1DHFR | |
| SCHEMBL6729320 | 0.72 | TSHR (0.36) | DHFROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL19745328 | 0.72 | SLC1A3 (0.45) | TSHR | |
| SCHEMBL31187955 | 0.71 | MAOA (0.45) | MAOAMAOBIDO1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | claimed |
| EP-4217357-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | Auckland Uniservices Limited (NZ) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022064430-A1 | NOVEL AMINOPYRIDINES AND THEIR USE IN TREATING CANCER | AUCKLAND UNISERVICES LIMITED (NZ) | 2022-03-31 | — | — | WO | disclosed |
| WO-2009056993-A2 | A PROCESS FOR THE SYNTHESIS OF RAMELTEON AND ITS INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-05-07 | — | — | WO | disclosed |
| US-7479491-B2 | Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors | NOVARTIS AG (CH) | 2009-01-20 | — | — | US | disclosed |
| US-6900353-B2 | Cyclopentyl sulfonamide derivatives | ELI LILLY AND COMPANY (US) | 2005-05-31 | — | — | US | disclosed |
| US-20050054692-A1 | Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors | SEIDELMANN DIETER (DE) | 2005-03-10 | — | — | US | disclosed |
| US-6818661-B2 | FOR THERAPY OF PSORIASIS, ARTHRITIS, SUCH AS RHEUMATOID ARTHRITIS, HAEMANGIOMA, ANGIOFIBROMA, EYE DISEASES SUCH AS DIABETIC RETINOPATHY, NEOVASCULAR GLAUCOMA, KIDNEY DISEASES SUCH AS GLOMERULONEPHRITIS, DIABETIC NEPHROPATHY | NOVARTIS AG (CH) | 2004-11-16 | — | — | US | disclosed |
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | CANTRELL BUDDY EUGENE (US) | 2004-04-08 | — | — | US | disclosed |
| US-20030176469-A1 | Anthranylalkyl and cycloalkyl amides and use thereof as vegf receptor inhibitors | NOVARTIS AG (CH) | 2003-09-18 | — | — | US | disclosed |
| EP-1334087-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-08-13 | — | — | EP | disclosed |
| WO-2002032858-A1 | CYCLOALKYLFLUOROSULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067984-A1 | Cyclopentyl sulfonamide derivatives | GRIN2A, GRIN1, GRIK5 | MAOA 1053/4885MAOB 1368/4885IDO1 2471/4885 |
| US-20050054692-A1 | Azanthranylalkyl and -cycloalkyl amides and their use as VEGF receptor inhibitors | KDR, VEGFA, FLT1 | MAOA 729/4885MAOB 987/4885IDO1 2031/4885 |
| US-20030176469-A1 | Anthranylalkyl and cycloalkyl amides and use thereof as vegf receptor inhibitors | KDR, FLT1, VEGFA | MAOA 1441/4885MAOB 2114/4885IDO1 2270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.